Erasca (ERAS) - Company Total Revenue

Erasca, Inc. is expanding its advanced oncology programs by completing clinical trials and optimizing R&D expenses. The company's ecosystem creates a comprehensive therapeutic barrier to suppress RAS mutations. Patent protection for targeted therapy formulas guarantees future monopoly profits. This sales volume chart is available in the GURU.Markets terminal, where 0.00 reflects the latest metric value, confirming the asset's fundamental stability.

Erasca Corp (ERAS) - Revenue and Sales Volume from 07/04/2022 to 11/13/2026

Comprehensive metric breakdowns and analytics for Erasca (ERAS)

- market price and analyst price targets:

Market Price Erasca Oncology|ERAS - Analyst Consensus Forecast

- market capitalization indicators:

Market Value Erasca, Inc.|ERAS - Total Company Value

- book value of equity indicators:

Accounting Value of a Share Erasca|ERAS - Book Capitalization|Market Capitalization to Book Value Ratio erasca.com|ERAS - Aggregate Company Assets

- company liabilities and liquidity data:

- earnings and valuation multiples indicators:

ERAS - Company Net Income|Net Profit Forecast Erasca, Inc.|ERAS - P/E Multiple|Projected Price to Earnings erasca.com|ERAS - Price/Earnings to Growth Multiple|Total Company Value to Operating Income Before Depreciation Ratio Erasca, Inc.|ERAS - Operating profit EBITDA|Net earnings per one share for the last twelve months Erasca|ERAS - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months erasca.com|ERAS - Earnings growth in current year|Earnings growth forecast for next year Erasca, Inc.

- company sales and revenue statistics:

ERAS - Company Revenue|Company Future Sales Erasca Oncology|ERAS - P/S Multiple|Forward Price-to-Revenue Multiple Erasca, Inc.

Summary company analysis:ERAS, Erasca Oncology

Erasca, Inc. operates as a research center, outsourcing production and clinical trials to third-party contractors. This indicator captures the daily volume of realized services and products, measuring the business's actual operational activity. Analyzing such flows allows investors to filter out short-term noise from sustainable fundamental growth. Sharp spikes require cautious interpretation to protect capital. Evaluate long-term trends based on the current sales of Erasca, Inc.

Competing companies